LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex: BPA) announced that a notice of allowance from the United States Patent & Trademark Office (USPTO) has been received covering the formulation used in Elestrin™ (estradiol gel), BioSante’s newly approved treatment for menopausal women. The notice of allowance is the official communication issued by the USPTO reporting that the application has successfully completed examination and that a patent will be issued after the applicant pays the necessary fee. This new patent will expire on June 23, 2021.
